



Immune Response and Vaccine Strategies against SARS-CoV-2

Guest Editors:

Dr. Shashank Tripathi

Microbiology & Cell Biology,
Indian Institute of Science,
Bangalore, India

Dr. Kesavardana Sannula

Biochemistry, Indian Institute of
Science, Bangalore, India

Deadline for manuscript
submissions:

closed (30 November 2023)

Message from the Guest Editors

Dear Colleagues,

The COVID-19 pandemic made us realize the importance of vaccines in protecting humans from unprecedented carnage caused by novel pathogens, especially fast-spreading respiratory viruses. We were fortunate to develop initial vaccine candidates against SARS-CoV-2 in an astonishingly short time. However, the virus has posed a formidable challenge through its constant antigenic drift and shift to evade vaccine-mediated and natural immunity. The durability of vaccine response has been another challenge, as the antibody responses against SARS-CoV-2 have been particularly short-lived. To develop better vaccines, it is crucial to understand the immune response against SARS-CoV-2, the immune correlates of protection, the determinants of the longevity of the immune response, and viral strategies to evade host immunity. In this proposed Special Issue, we will be inviting research articles and reviews from scientists across the globe specializing in this subject.

Dr. Shashank Tripathi

Dr. Kesavardana Sannula

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com